Previous studies showed that the IL-6/JAK-STAT3 pathway is abnormally hyperactivated in multiple tumor types and elevated expression of IL‐6 can stimulate hyperactivation of JAK/STAT3 signaling which usually leads to an unfavorable clinical outcome 43-45. Here, STAT3 is linked to neoplasm.